Trial Profile
A Phase IIb study of topic DAC-0060, a synthetic histone deacetylase inhibitor, plus Tazarotene in patients with cutaneous basal cell carcinoma (BCC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs DAC 0060 (Primary) ; Tazarotene
- Indications Basal cell cancer
- Focus Therapeutic Use
- 29 Jul 2014 New trial record